*Since the 2003 launch of Somatuline® Autogel® (lanreotide) in Australia, Ipsen has an ongoing commitment to research and development for patients.2-4

Supporting medication administration in the community

assistBEYOND is a patient support program designed to help you in the management of your patients prescribed Somatuline® Autogel® (lanreotide).

assistBEYOND nurses provide training on the administration of Somatuline® Autogel® in a community setting.

Program services include:

  • In-home training of patients or carers to facilitate independent ongoing drug administration; or
  • Training of health care professionals in a patient’s nominated general practice clinic to enable supported drug administration in the community

All patients enrolled in the program benefit from:

  • Patient education materials and access to the assistBEYOND website resources
  • Patient SMS service for script and appointment reminders
  • Ongoing access to nurse support via 1800 277 774

To enrol patients go to www.assistbeyond.com.au

For more information about the assistBEYOND Somatuline® Autogel® patient support program or to arrange an appointment to meet with an assistBEYOND nurse in your area, please call 1800 277 774 or email assist@nuevohealth.com.au


  1. Somatuline® Autogel® Approved Product Information.
  2. Adelman DT, et al. Med Devices (Auckl) 2012;5:107.
  3. Data on File, Ipsen.
  4. Australian Government Department of Health, The Pharmaceutical Benefits Scheme (PBS): Schedule of PBS Changes
    Dec 2018.http://www.pbs.gov.au/publication/schedule/2018/12/2018-12-01-general-soc.pdf (Accessed 10 July 2019)